Peripheral Blood Markers Associated with Immune-Related Adverse Effects in Patients Who Had Advanced Non-Small Cell Lung Cancer Treated with PD-1 Inhibitors

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34. doi:10.3322/caac.2155130620402
   PubMed Web of Science ®Google Scholar
• Hamid O, Robert C, Daud A, et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol. 2019;30(4):582–588. doi:10.1093/annonc/mdz01130715153
   PubMed Web of Science ®Google Scholar
• Sato Y, Fukuda N, Wang X, et al. Efficacy of nivolumab for head and neck cancer patients with primary sites and histological subtypes excluded from the checkmate-141 trial. Cancer Manag Res. 2020;12:4161–4168. doi:10.2147/CMAR.S24939332581587
   PubMed Web of Science ®Google Scholar
• Baxi S, Yang A, Gennarelli RL, et al. Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis. BMJ. 2018;360:k793. doi:10.1136/bmj.k79329540345
   PubMed Web of Science ®Google Scholar
• Martins F, Sofiya L, Sykiotis GP, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019;16(9):563–580. doi:10.1038/s41571-019-0218-031092901
   PubMed Web of Science ®Google Scholar
• Moslehi JJ, Salem JE, Sosman JA, Lebrun-Vignes B, Johnson DB. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet. 2018;391(10124):933. doi:10.1016/S0140-6736(18)30533-6
   PubMed Web of Science ®Google Scholar
• Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378(22):2078–2092. doi:10.1056/NEJMoa180100529658856
   PubMed Web of Science ®Google Scholar
• Horn L, Mansfield AS, Szczęsna A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379(23):2220–2229. doi:10.1056/NEJMoa180906430280641
   PubMed Web of Science ®Google Scholar
• Passat T, Touchefeu Y, Gervois N, Jarry A, Bossard C, Bennouna J. Physiopathological mechanisms of immune-related adverse events induced by anti-CTLA-4, anti-PD-1 and anti-PD-L1 antibodies in cancer treatment. Bull Cancer. 2018;105(11):1033–1041. doi:10.1016/j.bulcan.2018.07.00530244981
   PubMed Web of Science ®Google Scholar
• Das S, Johnson DB. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J Immunother Cancer. 2019;7(1):306. doi:10.1186/s40425-019-0805-831730012
   PubMed Web of Science ®Google Scholar
• Buder-Bakhaya K, Hassel JC. Biomarkers for clinical benefit of immune checkpoint inhibitor treatment-a review from the melanoma perspective and beyond. Front Immunol. 2018;9:1474. doi:10.3389/fimmu.2018.0147430002656
   PubMed Web of Science ®Google Scholar
• Michot JM, Bigenwald C, Champiat S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139–148. doi:10.1016/j.ejca.2015.11.01626765102
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhou S, Yang F, et al. Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis. JAMA Oncol. 2019;5(7):1008–1019. doi:10.1001/jamaoncol.2019.039331021376
   PubMed Web of Science ®Google Scholar
• Sun Y, Zhang L. The clinical use of pretreatment NLR, PLR, and LMR in patients with esophageal squamous cell carcinoma: evidence from a meta-analysis. Cancer Manag Res. 2018;10:6167–6179. doi:10.2147/CMAR.S17103530538564
   PubMed Web of Science ®Google Scholar
• Diem S, Schmid S, Krapf M, et al. Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung Cancer. 2017;111:176–181. doi:10.1016/j.lungcan.2017.07.02428838390
   PubMed Web of Science ®Google Scholar
• Bartlett EK, Flynn JR, Panageas KS, et al. High neutrophil-to-lymphocyte ratio (NLR) is associated with treatment failure and death in patients who have melanoma treated with PD-1 inhibitor monotherapy. Cancer. 2020;126(1):76–85. doi:10.1002/cncr.3250631584709
   PubMed Web of Science ®Google Scholar
• Giuliani J, Bonetti A. Financial toxicity and non-small cell lung cancer treatment: the optimization in the choice of immune check point inhibitors. Anticancer Res. 2019;39(7):3961–3965. doi:10.21873/anticanres.1355031262928
   PubMed Web of Science ®Google Scholar
• Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol. 2016;2(10):1346–1353. doi:10.1001/jamaoncol.2016.105127367787
   PubMed Web of Science ®Google Scholar
• Giuliani J, Bonetti A. Immune-checkpoint inhibitors in head and neck squamous cell carcinoma: cost-efficacy in second-line treatment based on programmed death-ligand 1 (PD-L1) level. Oral Oncol. 2019;97:143–145. doi:10.1016/j.oraloncology.2019.08.01031431352
   PubMed Web of Science ®Google Scholar
• Hasan Ali O, Berner F, Bomze D, et al. Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors. Eur J Cancer. 2019;107:8–14. doi:10.1016/j.ejca.2018.11.00930529903
   PubMed Web of Science ®Google Scholar
• Dubin K, Callahan MK, Ren B, et al. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat Commun. 2016;7(1):10391. doi:10.1038/ncomms1039126837003
   PubMed Web of Science ®Google Scholar
• Chaput N, Lepage P, Coutzac C, et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol. 2017;28(6):1368–1379. doi:10.1093/annonc/mdx10828368458
   PubMed Web of Science ®Google Scholar
• Toi Y, Sugawara S, Sugisaka J, et al. Profiling preexisting antibodies in patients treated with anti-PD-1 therapy for advanced non-small cell lung cancer. JAMA Oncol. 2019;5(3):376–383. doi:10.1001/jamaoncol.2018.586030589930
   PubMed Web of Science ®Google Scholar
• Pavan A, Calvetti L, Dal Maso A, et al. Peripheral blood markers identify risk of immune-related toxicity in advanced non-small cell lung cancer treated with immune-checkpoint inhibitors. Oncol. 2019;24(8):1128–1136. doi:10.1634/theoncologist.2018-0563
   Google Scholar
• Peng L, Wang Y, Liu F, et al. Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors. Cancer Immunol Immunother. 2020;69(9):1813–1822. doi:10.1007/s00262-020-02585-w32350592
   PubMed Web of Science ®Google Scholar
• Gu XB, Tian T, Tian XJ, Zhang XJ. Prognostic significance of neutrophil-to-lymphocyte ratio in non-small cell lung cancer: a meta-analysis. Sci Rep. 2015;5(1):12493. doi:10.1038/srep1249326205001
   PubMed Web of Science ®Google Scholar
• Liu ZL, Zeng TT, Zhou XJ, et al. Neutrophil-lymphocyte ratio as a prognostic marker for chemotherapy in advanced lung cancer. Int J Biol Markers. 2016;31(4):e395–e401. doi:10.5301/jbm.500022227416842
   PubMed Web of Science ®Google Scholar
• Berner F, Bomze D, Diem S, et al. Association of checkpoint inhibitor-induced toxic effects with shared cancer and tissue antigens in non-small cell lung cancer. JAMA Oncol. 2019;5(7):1043–1047. doi:10.1001/jamaoncol.2019.040231021392
   PubMed Web of Science ®Google Scholar